Catalog No.: PC-21535Not For Human Use, Lab Use Only.
ATN-161 (Ac-PHSCN-NH2) is a small peptide inhibitor of integrin alpha5 beta1 (α5β1) and alphavbeta3 (αvβ3) with binding Kd of 1.0 and 0.6 uM, respectively, inhibits breast cancer growth and metastasis.
ATN-161 (Ac-PHSCN-NH2) is a small peptide inhibitor of integrin alpha5 beta1 (α5β1) and alphavbeta3 (αvβ3) with binding Kd of 1.0 and 0.6 uM, respectively, inhibits breast cancer growth and metastasis. ATN-161 forms a disulfide bond with its integrin target. ATN-161 (20 uM) significantly inhibits MAPK phosphorylation with maximal effects in MDA-MB-231 cells. ATN-161 (1 mg/kg) inhibits MDA-MB-231 tumor growth in vivo, causes a significant dose-dependent decrease in tumor volume and either completely blocked or caused a marked decrease in the incidence and number of skeletal as well as soft tissue metastases.
